These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 26259849)

  • 21. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment.
    Turk D; Boeri M; Abraham L; Atkinson J; Bushmakin AG; Cappelleri JC; Hauber B; Klein K; Russo L; Viktrup L; Walsh D
    Osteoarthritis Cartilage; 2020 Sep; 28(9):1202-1213. PubMed ID: 32652238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
    Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
    Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
    van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
    Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.
    Augustovski F; Beratarrechea A; Irazola V; Rubinstein F; Tesolin P; Gonzalez J; Lencina V; Scolnik M; Waimann C; Navarta D; Citera G; Soriano ER
    Value Health; 2013; 16(2):385-93. PubMed ID: 23538191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
    Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
    Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.
    Mardan J; Hussain MA; Allan M; Grech LB
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1273-1295. PubMed ID: 34464209
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
    Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
    Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient preferences and assessment of likely adherence to hepatitis C virus treatment.
    Brett Hauber A; Mohamed AF; Beam C; Medjedovic J; Mauskopf J
    J Viral Hepat; 2011 Sep; 18(9):619-27. PubMed ID: 20579276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
    Marshall T; Pugh A; Fairchild A; Hass S
    Value Health; 2017 Dec; 20(10):1383-1393. PubMed ID: 29241898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments.
    Poulos C; Hauber AB; González JM; Turpcu A
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1008-15. PubMed ID: 24339373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs.
    Atkinson-Clark E; Charokopou M; Van Osselaer N; Hiligsmann M
    Epilepsy Behav; 2018 Feb; 79():58-67. PubMed ID: 29248866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient preferences for Interferon-beta in Iran: A discrete choice experiment.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F; Etemadifar M; Ashtari F; Sabzghabaee AM; Amirsadri MR
    PLoS One; 2018; 13(3):e0193090. PubMed ID: 29590134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis.
    Bauer B; Brockmeier B; Devonshire V; Charbonne A; Wach D; Hendin B
    Neurodegener Dis Manag; 2020 Dec; 10(6):369-382. PubMed ID: 32873160
    [No Abstract]   [Full Text] [Related]  

  • 39. A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.
    Ridyard CH; Dawoud DM; Tuersley LV; Hughes DA
    Patient; 2016 Aug; 9(4):281-92. PubMed ID: 26792584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.